A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer Recurrent

Interventions

BIOLOGICAL: Raludotatug Deruxtecan
DRUG: Carboplatin
DRUG: Paclitaxel
BIOLOGICAL: Bevacizumab
DRUG: Rescue Medication
BIOLOGICAL: Pembrolizumab
DRUG: Gemcitabine
DRUG: Pegylated liposomal doxorubicin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]